Kimryn Rathmell: Big announcement from FDA regarding diversity in clinical trials
Kimryn Rathmell shared on X:
“Big announcement from FDA regarding diversity in clinical trials.
U.S. FDA has drafted long-awaited guidance aimed at empowering drug companies and medical device makers to enroll more people of color and women in clinical trials.”
Additional information.
Source: Kimryn Rathmell/X
Dr. Kimryn Rathmell is a distinguished leader and researcher in the field of kidney cancer. Specializing in the research and treatment of complex and hereditary kidney cancers.
She has held leadership positions with organizations such as the American Society of Clinical Oncology and the American Society for Clinical Investigation, she has been elected to esteemed academies including the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023